HANSA MEDICAL AB ORD news, videos and press releases
For more news please use our advanced search feature.
HANSA MEDICAL AB ORD - More news...
HANSA MEDICAL AB ORD - More news...
- Hansa Biopharma interim report January-March 2024
- Hansa Biopharma interim report January-March 2024
- Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance
- Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance
- Hansa Biopharma publishes 2023 Annual and Sustainability Reports
- Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer
- Hansa Biopharma Year-end report January-December 2023
- Hansa Biopharma Year-end report January-December 2023
- Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference
- Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference
- Hansa Biopharma Nomination Committee formed
- Hansa Biopharma Nomination Committee formed
- Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 trial in Guillain-Barré Syndrome (GBS)
- Hansa Biopharma plans restructuring to strengthen long-term competitiveness and advance key deliverables
- Hansa Biopharma plans restructuring to strengthen long-term competitiveness and advance key deliverables
- Hansa Biopharma Interim Report January-September 2023
- Hansa Biopharma Interim Report January-September 2023
- Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study
- Hansa Biopharma announces encouraging high-level results for first-in-human trial of HNSA-5487
- Dr. Hitto Kaufmann appointed Chief Scientific Officer of Hansa Biopharma
- Hansa Biopharma: Increase of the number of votes
- Hansa Biopharma half year report 2023
- Hansa Biopharma half year report 2023
- First patient treated with imlifidase in an investigator-initiated Phase 2 study in ANCA-associated vasculitis
- Idefirix (imlifidase) receives provisional approval in Australia as desensitization treatment in highly sensitized patients prior to kidney transplantation
- Hansa Biopharma to host conference call to provide half year results for January-June 2023 and a Business Update
- Hansa Biopharma to host conference call to provide half year results for January-June 2023 and a Business Update
- Hansa Biopharma AB recognizes a write-up of SEK 1.430 billion in intangible assets related to Idefirix in the financial statements of the parent company - no impact on the consolidated financials
- Hansa Biopharma AB recognizes a write-up of SEK 1.430 billion in intangible assets related to Idefirix in the financial statements of the parent company - no impact on the consolidated financials
- Hansa announces first patient dosed with imlifidase in a global pivotal phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease
